Figure 3From: Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment The distribution of timing of HCV RNA undetectable after the initiation of treatment at weeks 2, 4, 8, and 12 in comparison with TaqMan and qualitative Amplicor assays. SVR, sustained virological response.Back to article page